Description: Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
Home Page: www.egetis.com
Klara Norra Kyrkogata 26
Stockholm,
111 22
Sweden
Phone:
46 86 79 72 10
Officers
| Name | Title |
|---|---|
| Mr. Nicklas Westerholm | Chief Exec. Officer |
| Mr. Torsten Almén | Founder |
| Dr. Ingemar Lundström | Founder |
| Dr. Louis Joseph Ignarro Ph.D. | Founder |
| Associate Prof. Heidi Brurok | Founder |
| Dr. Rob Towart | Founder |
| Dr. Yilmaz Mahshid | Chief Financial Officer |
| Dr. Jacques Näsström M.B.A., MBA, Ph.D. | Chief Scientific Officer |
| Dr. Karl Hard Ph.D. | VP, Head of Investor Relations & Communication |
| Mr. Peter Verwaijen | Global Head of Marketing & Brand Strategy |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.523 |
| Price-to-Sales TTM: | 42.386 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 17 |